KSC · 096760.KS
JW Holdings Corporation
₩3,965-₩35 (-0.88%)
JW Holdings Corporation’s quoted price sits in the upper half of its reported 52-week range, 16.0% below the high.
Loading market information…
KSC · 271980.KS · KRW
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · KRW. Historical prices are not a forecast.
Jeil Pharmaceutical Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 55.42% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Jeil Pharmaceutical Co.,Ltd’s forward annual dividend is ₩50 per share, paid annual. The forward yield is 0.58% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Jeil Pharmaceutical Co.,Ltd’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Primarily active within South Korea, Jeil Pharmaceutical Co.,Ltd dedicates itself to the development and supply of a broad spectrum of pharmaceutical goods. Its product offerings address numerous therapeutic categories, including antibiotics, gastrointestinal health, cardiovascular conditions, neuropsychiatric disorders, cancer (oncology), endocrine imbalances, urological issues, viral infections, and antihistamine remedies. Furthermore, the company extends its market reach globally, exporting its merchandise to roughly 40 nations across the ASEAN bloc, Central and South America, Africa, and other international destinations. Founded in 1959, Jeil Pharmaceutical Co.,Ltd maintains its headquarters in Seoul, South Korea.
Latest available per-share figures in KRW. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:38 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₩3,965-₩35 (-0.88%)
JW Holdings Corporation’s quoted price sits in the upper half of its reported 52-week range, 16.0% below the high.
₩9,370+₩10 (+0.11%)
REYON Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 29.02% below the high.
₩35,600+₩200 (+0.56%)
Chong Kun Dang Holdings Corp.’s quoted price sits in the lower half of its reported 52-week range, 35.97% below the high.
₩7,650-₩40 (-0.52%)
Samil Pharmaceutical Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 40.51% below the high.
₩8,070-₩160 (-1.94%)
Hana Pharm Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 32.3% below the high.
₩5,090-₩220 (-4.14%)
AptaBio Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 53.26% below the high.
₩6,960+₩50 (+0.72%)
Ilyang Pharmaceutical Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 57.14% below the high.
₩1,203-₩27 (-2.2%)
SAMSUNG PHARM. Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 48.15% below the high.
